SG11201901759XA - Methods for treating ovarian cancer - Google Patents

Methods for treating ovarian cancer

Info

Publication number
SG11201901759XA
SG11201901759XA SG11201901759XA SG11201901759XA SG11201901759XA SG 11201901759X A SG11201901759X A SG 11201901759XA SG 11201901759X A SG11201901759X A SG 11201901759XA SG 11201901759X A SG11201901759X A SG 11201901759XA SG 11201901759X A SG11201901759X A SG 11201901759XA
Authority
SG
Singapore
Prior art keywords
international
pct
applicant
ovarian cancer
rule
Prior art date
Application number
SG11201901759XA
Other languages
English (en)
Inventor
Gary Hattersley
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of SG11201901759XA publication Critical patent/SG11201901759XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201901759XA 2016-09-27 2017-09-27 Methods for treating ovarian cancer SG11201901759XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662400495P 2016-09-27 2016-09-27
PCT/US2017/053834 WO2018064231A1 (en) 2016-09-27 2017-09-27 Methods for treating ovarian cancer

Publications (1)

Publication Number Publication Date
SG11201901759XA true SG11201901759XA (en) 2019-04-29

Family

ID=61760096

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901759XA SG11201901759XA (en) 2016-09-27 2017-09-27 Methods for treating ovarian cancer
SG10202104282SA SG10202104282SA (en) 2016-09-27 2017-09-27 Methods for treating ovarian cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202104282SA SG10202104282SA (en) 2016-09-27 2017-09-27 Methods for treating ovarian cancer

Country Status (21)

Country Link
US (2) US20200009085A1 (ko)
EP (1) EP3518911B1 (ko)
JP (1) JP2019532934A (ko)
KR (2) KR20190058568A (ko)
CN (1) CN109715149A (ko)
AU (1) AU2017336564A1 (ko)
BR (1) BR112019004276A2 (ko)
CA (1) CA3036568A1 (ko)
CY (1) CY1125266T1 (ko)
ES (1) ES2898072T3 (ko)
HR (1) HRP20211804T1 (ko)
HU (1) HUE057064T2 (ko)
IL (1) IL265537B2 (ko)
LT (1) LT3518911T (ko)
MX (1) MX2019003311A (ko)
PL (1) PL3518911T3 (ko)
PT (1) PT3518911T (ko)
RS (1) RS62660B1 (ko)
SG (2) SG11201901759XA (ko)
SI (1) SI3518911T1 (ko)
WO (1) WO2018064231A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020311337A1 (en) * 2019-07-07 2022-01-20 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
CN1927815A (zh) * 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
US20110009387A1 (en) * 2007-06-12 2011-01-13 Andrea Dawn Basso-Porcaro Histone h2ax (hh2ax) biomarker for fti sensitivity
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
CA2915534A1 (en) * 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
CN104436194B (zh) * 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
EP3116497A2 (en) * 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US9980947B2 (en) * 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
CN105848374A (zh) * 2015-01-12 2016-08-10 芋头科技（杭州）有限公司 一种灯光控制系统及方法
CA2973373C (en) * 2015-01-28 2023-08-01 Corex, Llc Battery enclosure for sterilizeable surgical tools having thermal insulation
IL297369B1 (en) * 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc RAD for use in a method to treat mutant estrogen receptor positive breast cancer or mutant estrogen receptor positive ovarian cancer

Also Published As

Publication number Publication date
EP3518911A1 (en) 2019-08-07
RU2019108382A (ru) 2020-10-29
JP2019532934A (ja) 2019-11-14
SG10202104282SA (en) 2021-06-29
ES2898072T3 (es) 2022-03-03
HRP20211804T1 (hr) 2022-02-18
CN109715149A (zh) 2019-05-03
IL265537B (en) 2022-12-01
EP3518911A4 (en) 2020-05-13
CY1125266T1 (el) 2023-03-24
KR20230152814A (ko) 2023-11-03
MX2019003311A (es) 2019-07-08
RS62660B1 (sr) 2021-12-31
SI3518911T1 (sl) 2022-02-28
RU2019108382A3 (ko) 2020-12-28
BR112019004276A2 (pt) 2019-06-04
WO2018064231A1 (en) 2018-04-05
CA3036568A1 (en) 2018-04-05
AU2017336564A1 (en) 2019-03-14
PL3518911T3 (pl) 2022-02-07
LT3518911T (lt) 2021-12-10
EP3518911B1 (en) 2021-08-25
IL265537A (en) 2019-05-30
PT3518911T (pt) 2021-11-11
HUE057064T2 (hu) 2022-04-28
US20200009085A1 (en) 2020-01-09
IL265537B2 (en) 2023-04-01
KR20190058568A (ko) 2019-05-29
US20230129787A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201805001UA (en) Method of treating influenza a
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900361RA (en) Methods of treating prostate cancer
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201810123SA (en) Treatment of intrahepatic cholestatic diseases
SG11201906383WA (en) A layered medical data computer architecture